Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | PPID | Q08752 | 3/20 | 0.41 |
| ▸ | PPIG | Q13427 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557291 | 0.90 | PPID (0.42) | PREPFAPPPIDPPIGLMNA | |
| SCHEMBL21348091 | 0.80 | ACE2 (0.48) | PREPFAPLMNAACEREN | |
| SCHEMBL30051731 | 0.78 | REN (0.47) | LMNAACEREN | |
| SCHEMBL23572657 | 0.78 | APLNR (0.39) | PPIDPPIGTSHR | |
| SCHEMBL23600801 | 0.78 | APLNR (0.39) | PPIDPPIGTSHR | |
| SCHEMBL23572656 | 0.78 | APLNR (0.39) | PPIDPPIGTSHR | |
| SCHEMBL30051518 | 0.77 | ACE (0.46) | LMNAACERENTSHR | |
| SCHEMBL30051793 | 0.77 | ACE (0.49) | LMNAACEREN | |
| SCHEMBL1371104 | 0.76 | OPRM1 (0.44) | — | |
| SCHEMBL23572622 | 0.76 | CXCL8 (0.48) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | PREP 381/4885FAP 1176/4885PPID 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.